Inmune Bio, Inc. (INMB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.44+7.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
INmune Bio is advancing with strategic partnerships like the one with Anthony Nolan. The company has improved management execution, shown by amendments reducing warrant exercise prices. Analysts expect revenue to grow 100% next year from zero. The stock price has risen 41.5% in 63 days, reflecting optimism.
INmune Bio remains loss-making with negative EPS of -$0.6 expected in 2026. Revenue estimates are low at $6.36 million for 2027, showing limited commercial traction. The company faces elevated risk and has a high price-to-sales ratio of 925, indicating overvaluation.
The market prices in about 100% revenue growth next year and a 29% implied growth over three years. Our fair value is $0.8, matching consensus, but the company’s loss-making status and low revenues suggest these growth expectations may be optimistic.
Breaks if: Warrant terms revert or worsen materially
Entered into an amendment with certain holders of April 2024 Warrants, reducing the exercise price.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is working on innovative treatments, particularly for early Alzheimer's disease, but it is currently loss-making and faces high risks.
The market seems to have priced in a high valuation premium compared to peers, reflecting the potential of its drug pipeline. However, this premium may not fully account for the company's current losses and the inherent risks in its sector.
Management is making progress with its key priorities, including advancing XPro1595 and regulatory submissions for CORDStrom. However, the company remains loss-making, and while recent performance is stable, it operates in a high-risk environment.
The future of INMB depends on the performance of sector leaders like VRTX, REGN, and ARGX, as well as the company's ability to navigate regulatory pathways and manage its capital effectively. Economic conditions and job reports could also impact sentiment in the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The regulatory filing and approval path for CORDStrom in RDEB is advancing. This UK regulatory alignment supports the approval path for CORDStrom. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens or remains at -0.6 or lower in FY27
Breaks if: YoY revenue growth falls below 100% in FY27
Advance strategic partnership with Anthony Nolan to support development and commercialization efforts.
Newly stated in 2026-Q1. The company formalized its strategic partnership with Anthony Nolan through an amended and restated Material Transfer and License Agreement. This partnership supports development efforts. No financial metrics are provided, so progress is limited to the agreement execution.
“INmune Bio entered into amended and restated Material Transfer and License Agreement with Anthony Nolan on April 29, 2026.”
Over the next 1 to 3 years, INMB's trajectory will rely on its clinical advancements and the broader healthcare landscape. Not investment advice.